SMART Clinical Trial: What Women Need to Know About TAVR for Small Aortic Valves

9 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
https://www.Heart-Valve-Surgery.com – Are women with symptomatic severe aortic stenosis still under-treated? What did the two-year SMART Clinical Trial reveal about TAVR valve performance for women with small annulus anatomy? How can these findings help patients make better treatment decisions?

To answer these important questions, HeartValveSurgery.com founder Adam Pick spoke with Dr. Angela Lowenstern, Interventional Cardiologist at Vanderbilt Health in Nashville, Tennessee. In this educational video, Dr. Lowenstern explains why women with symptomatic severe aortic stenosis are often diagnosed later, treated less often, and how the two-year SMART clinical trial may help improve valve selection for women with smaller anatomy. In this video, Dr. Lowenstern discusses:

- Why women with severe aortic stenosis are often under-treated
- Why small annulus anatomy is especially important for female patients
- What made the SMART clinical trial unique, including 87% women enrollment
- The two-year outcomes for self-expanding versus balloon-expandable TAVR valves
- Why the Medtronic Evolut self-expanding valve showed better valve hemodynamics
- Potential long-term durability implications of lower valve dysfunction
- The risks associated with TAVR, including bleeding, stroke, pacemaker, and heart attack
- Why women should be proactive, ask hard questions, and discuss valve choice with their physicians

To learn more, please visit https://www.TAVRforWomen.com. If you would like to schedule an appointment or seek a second opinion with Dr. Angela Lowenstern, please contact Vanderbilt Health in Nashville, Tennessee at https://www.vanderbilthealth.com/doctors/lowenstern-angela.
Categoria
Cardiology
Commenta per primo questo video.

Prossimo